161 related articles for article (PubMed ID: 33516806)
1. Decreasing treatment burden in HPV-related OPSCC: A systematic review of clinical trials.
Iorio GC; Arcadipane F; Martini S; Ricardi U; Franco P
Crit Rev Oncol Hematol; 2021 Apr; 160():103243. PubMed ID: 33516806
[TBL] [Abstract][Full Text] [Related]
2. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Masterson L; Moualed D; Masood A; Dwivedi RC; Benson R; Sterling JC; Rhodes KM; Sudhoff H; Jani P; Goon P
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD010271. PubMed ID: 24532092
[TBL] [Abstract][Full Text] [Related]
3. Role of TORS as De-Escalation Strategy in HPV-Related Oropharyngeal Cancer, What We Need to Know.
Molteni G; Bassani S; Arsie AE; Zampieri E; Mannelli G; Orlandi E; Bossi P; De Virgilio A
Healthcare (Basel); 2024 May; 12(10):. PubMed ID: 38786424
[TBL] [Abstract][Full Text] [Related]
4. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.
Masterson L; Moualed D; Liu ZW; Howard JE; Dwivedi RC; Tysome JR; Benson R; Sterling JC; Sudhoff H; Jani P; Goon PK
Eur J Cancer; 2014 Oct; 50(15):2636-48. PubMed ID: 25091798
[TBL] [Abstract][Full Text] [Related]
5. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
[TBL] [Abstract][Full Text] [Related]
6. Quality of Life and Depression Symptoms After Therapy De-Escalation in HPV+ Oropharyngeal Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
Panwar A; Shah S; Reid AE; Lydiatt W; Holcomb AJ; Osmolak A; Coughlin A; Militsakh O; Su YB; Mirmiran A; Huang TS; Nolan N; Duckert R; Barney C; Chiu M; Nguyen C; Sayles H; Ganti AK; Lindau R
JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):429-435. PubMed ID: 38573597
[TBL] [Abstract][Full Text] [Related]
7. Treatment de-intensification strategies for head and neck cancer.
Kelly JR; Husain ZA; Burtness B
Eur J Cancer; 2016 Nov; 68():125-133. PubMed ID: 27755996
[TBL] [Abstract][Full Text] [Related]
8. De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research.
Petar S; Marko S; Ivica L
Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4599-4603. PubMed ID: 33599841
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma.
Yamamoto Y; Takemoto N; Michiba T; Seo Y; Isohashi F; Otani K; Suzuki M; Fujii T; Yoshii T; Mitani K; Yasui T; Cho H; Tomita Y; Morii E; Teshima T; Ogawa K; Inohara H
Int J Clin Oncol; 2019 Jun; 24(6):640-648. PubMed ID: 30694402
[TBL] [Abstract][Full Text] [Related]
10. [De-escalation concepts for chemoradiotherapy of HPV-positive oropharyngeal carcinomas: pros and cons].
Rühle A; Nicolay NH
HNO; 2021 Apr; 69(4):278-284. PubMed ID: 33048200
[TBL] [Abstract][Full Text] [Related]
11. It is not just IMRT: Human papillomavirus related oropharynx squamous cell carcinoma is associated with better swallowing outcomes after definitive chemoradiotherapy.
Naik M; Ward MC; Bledsoe TJ; Kumar AM; Rybicki LA; Saxton JP; Burkey BB; Greskovich JF; Adelstein DJ; Koyfman SA
Oral Oncol; 2015 Aug; 51(8):800-4. PubMed ID: 25977228
[TBL] [Abstract][Full Text] [Related]
12. Present and Future of De-intensification Strategies in the Treatment of Oropharyngeal Carcinoma.
De Virgilio A; Costantino A; Mercante G; Petruzzi G; Sebastiani D; Franzese C; Scorsetti M; Pellini R; Malvezzi L; Spriano G
Curr Oncol Rep; 2020 Jul; 22(9):91. PubMed ID: 32643045
[TBL] [Abstract][Full Text] [Related]
13. Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives.
Mirghani H; Amen F; Blanchard P; Moreau F; Guigay J; Hartl DM; Lacau St Guily J
Int J Cancer; 2015 Apr; 136(7):1494-503. PubMed ID: 24622970
[TBL] [Abstract][Full Text] [Related]
14. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.
Frakes JM; Naghavi AO; Demetriou SK; Strom TJ; Russell JS; Kish JA; McCaffrey JC; Otto KJ; Padhya TA; Harrison LB; Trotti AM; Caudell JJ
Cancer; 2016 Feb; 122(4):634-41. PubMed ID: 26565997
[TBL] [Abstract][Full Text] [Related]
15. [Treatment de-intensification strategies for HPV-driven oropharyngeal cancer: A short review].
Lahmamssi C; Guy JB; Benchekroun N; Bouchbika Z; Taoufik N; Jouhadi H; Sahraoui S; Benider A; Ben Mrad M; Jmour O; Bousarsar A; Lan ML; Lei Q; Benna M; Moslemi D; Vallard A; Magné N
Cancer Radiother; 2020 Jun; 24(3):258-266. PubMed ID: 32229067
[TBL] [Abstract][Full Text] [Related]
16. Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma.
Gabani P; Lin AJ; Barnes J; Oppelt P; Adkins DR; Rich JT; Zevallos JP; Daly MD; Gay HA; Thorstad WL
Radiother Oncol; 2019 May; 134():81-88. PubMed ID: 31005228
[TBL] [Abstract][Full Text] [Related]
17. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial.
Nichols AC; Lang P; Prisman E; Berthelet E; Tran E; Hamilton S; Wu J; Fung K; de Almeida JR; Bayley A; Goldstein DP; Eskander A; Husain Z; Bahig H; Christopoulous A; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Mendez A; Winquist E; Read N; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Corsten M; Rajaraman M; Johnson-Obaseki S; Eapen L; Odell M; Chandarana S; Banerjee R; Dort J; Matthews TW; Hart R; Kerr P; Dowthwaite S; Gupta M; Zhang H; Wright J; Parker C; Wehrli B; Kwan K; Theurer J; Palma DA
BMC Cancer; 2020 Feb; 20(1):125. PubMed ID: 32059705
[TBL] [Abstract][Full Text] [Related]
18. Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin.
Swiecicki PL; Li P; Bellile E; Stucken C; Malloy K; Shuman A; Spector ME; Chinn S; Casper K; McLean S; Moyer J; Chepeha D; Wolf GT; Prince M; Bradford C; Nyati M; Eisbruch A; Worden FP; Jolly S; Mierzwa M
Head Neck; 2020 Aug; 42(8):1728-1737. PubMed ID: 31989702
[TBL] [Abstract][Full Text] [Related]
19. Special Issue about Head and Neck Cancers: HPV Positive Cancers.
Economopoulou P; Kotsantis I; Psyrri A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403287
[TBL] [Abstract][Full Text] [Related]
20. Gastrostomy tube dependence and patient-reported quality of life outcomes based on type of treatment for human papillomavirus-associated oropharyngeal cancer: Systematic review and meta-analysis.
Quan DL; Sukari A; Nagasaka M; Kim H; Cramer JD
Head Neck; 2021 Nov; 43(11):3681-3696. PubMed ID: 34323332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
